Medications for Obesity

医学 利拉鲁肽 减肥 奥利斯特 不利影响 肥胖 芬特明 安非他酮 恶心 食欲 2型糖尿病 内科学 内分泌学 糖尿病 戒烟 病理
作者
Kimberly A. Gudzune,Robert F. Kushner
出处
期刊:JAMA [American Medical Association]
卷期号:332 (7): 571-571 被引量:193
标识
DOI:10.1001/jama.2024.10816
摘要

Importance: Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations: AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants). Conclusion and Relevance: Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
谨慎翎完成签到 ,获得积分10
1秒前
PPP完成签到,获得积分0
2秒前
栗子发布了新的文献求助10
2秒前
2秒前
3秒前
ding应助HYH采纳,获得10
5秒前
xinyuzhang完成签到,获得积分10
6秒前
蓝天发布了新的文献求助10
6秒前
顽主完成签到,获得积分10
7秒前
lili发布了新的文献求助10
7秒前
Fighting发布了新的文献求助10
7秒前
9秒前
领导范儿应助zhangzhibin采纳,获得10
11秒前
11秒前
稳重擎苍完成签到,获得积分10
14秒前
15秒前
15秒前
小二郎应助山顶洞人采纳,获得10
15秒前
聂先生完成签到,获得积分10
15秒前
研友_Lw7OvL完成签到 ,获得积分10
15秒前
神奇海螺完成签到,获得积分10
17秒前
123321完成签到,获得积分10
18秒前
快乐松思完成签到,获得积分10
18秒前
鲤鱼幻枫完成签到,获得积分10
20秒前
红炉点血完成签到,获得积分10
20秒前
李陈发布了新的文献求助10
20秒前
怜然完成签到,获得积分10
20秒前
传奇3应助xiaoyi采纳,获得10
20秒前
无奈的书琴完成签到 ,获得积分10
21秒前
蠢萌的小哈完成签到 ,获得积分10
22秒前
小狼完成签到,获得积分20
23秒前
23秒前
田様应助科研通管家采纳,获得10
23秒前
JamesPei应助科研通管家采纳,获得10
23秒前
无极微光应助科研通管家采纳,获得20
23秒前
23秒前
Akim应助科研通管家采纳,获得10
23秒前
冷泠凛应助科研通管家采纳,获得10
23秒前
共享精神应助科研通管家采纳,获得10
23秒前
高分求助中
Psychopathic Traits and Quality of Prison Life 1000
Chemistry and Physics of Carbon Volume 18 800
The formation of Australian attitudes towards China, 1918-1941 660
Signals, Systems, and Signal Processing 610
天津市智库成果选编 600
Forced degradation and stability indicating LC method for Letrozole: A stress testing guide 500
全相对论原子结构与含时波包动力学的理论研究--清华大学 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6451429
求助须知:如何正确求助?哪些是违规求助? 8263349
关于积分的说明 17607645
捐赠科研通 5516239
什么是DOI,文献DOI怎么找? 2903676
邀请新用户注册赠送积分活动 1880634
关于科研通互助平台的介绍 1722655